Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device. Benzinga reached out to DexCom for comments and is yet ...
The Stelo is available to anyone who wants to monitor their blood glucose, no prescription needed. But as an active adult without diabetes, are these extra data points worth $99 per month?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results